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ABSTRACT: Novel antibiotics are urgently needed. The
troponoids [tropones, tropolones, and α-hydroxytropolones
(α-HT)] can have anti-bacterial activity. We synthesized or
purchased 92 troponoids and evaluated their antibacterial
activities against Staphylococcus aureus, Escherichia coli,
Acinetobacter baumannii, and Pseudomonas aeruginosa. Pre-
liminary hits were assessed for minimum inhibitory concen-
trations (MIC80) and cytotoxicity (CC50) against human
hepatoma cells. Sixteen troponoids inhibited S. aureus/E. coli/
A. baumannii growth by ≥80% growth at <30 μM with CC50
values >50 μM. Two selected tropolones (63 and 285)
inhibited 18 methicillin-resistant S. aureus (MRSA) strains
with similar MIC80 values as against a reference strain. Two selected thiotropolones (284 and 363) inhibited multidrug-resistant
(MDR) E. coli with MIC80 ≤30 μM. One α-HT (261) inhibited MDR-A. baumannii with MIC80 ≤30 μM. This study opens
new avenues for development of novel troponoid antibiotics to address the critical need to combat MDR bacterial infections.
■ INTRODUCTION
The emergence of antimicrobial-resistant bacteria is a rapidly
growing concern for public health. The economic cost of
bacterial resistance is estimated to be around $55 billion
annually in the United States alone.1 In February 2017, the
World Health Organization (WHO) announced that the
highest priority organisms for development of new antibiotics
are carbapenem-resistant Acinetobacter, Pseudomonas aerugino-
sa, and the Enterobacteriaceae. The ﬁrst two second-priority
organisms are vancomycin-resistant Enterococcus faecium and
methicillin-resistant, vancomycin intermediate and resistant
Staphylococcus aureus. The discovery and development of novel
antibiotic compounds has been slow. Resistant bacteria spread
and cause infections at increasing rates, and thus there is an
urgent need to develop novel classes of potent antibiotics.2,3 In
addition, most new antibiotics are derivatives of existing drugs;
thus, bacterial targets have already been under strong selection
to develop resistance.
Troponoid compounds include the tropones, tropolones,
and hydroxytropolones and their derivatives. All of them have a
seven-carbon ring and possesses a nonbenzenoid aromatic
character.4 Tropone (2,4,6-cycloheptatrien-1-one) has a
ketone group on the troponoid ring. Tropolone (2-hydroxy-
2,4,6-cycloheptatrien-1-one) has an alcohol (or an enol
including the double bond) group next to the ketone. α-
Received: July 23, 2018
Accepted: October 19, 2018
Published: November 8, 2018
Article
http://pubs.acs.org/journal/acsodfCite This: ACS Omega 2018, 3, 15125−15133
© 2018 American Chemical Society 15125 DOI: 10.1021/acsomega.8b01754
ACS Omega 2018, 3, 15125−15133
This is an open access article published under an ACS AuthorChoice License, which permits
copying and redistribution of the article or any adaptations for non-commercial purposes.
D
ow
nl
oa
de
d 
vi
a 
W
A
SH
IN
G
TO
N
 U
N
IV
 o
n 
Ja
nu
ar
y 
10
, 2
01
9 
at
 2
3:
39
:0
6 
(U
TC
). 
Se
e 
ht
tp
s:/
/p
ub
s.a
cs
.o
rg
/sh
ar
in
gg
ui
de
lin
es
 fo
r o
pt
io
ns
 o
n 
ho
w
 to
 le
gi
tim
at
el
y 
sh
ar
e 
pu
bl
ish
ed
 a
rti
cl
es
. 
Hydroxytropolone (α-HT) has an additional alcohol group on
C7 of the troponoid ring (Figure 1).
Tropolone derivatives can have antibacterial,5−9 antivi-
ral,10−14 antifungal properties,15 anti-tumor, anti-inﬂammatory,
antioxidant and insecticidal.16,17 Because troponoids have high
pharmacological activity, development of convenient methods
of synthesis of their new derivatives and the search among the
derivatives for molecules with antibacterial activity against drug
resistant bacteria are important. Recently, Dr. Ryan Murelli
and coworkers pioneered a novel approach to generate poly-
substituted α-HTs from readily available precursor com-
pounds,18 and Dr. Bahaa Elgendy and coworkers explored
the synthesis of novel thiotropolones. Together, these provided
us the unique opportunity to evaluate the anti-microbial
activities of a wide range of chemically diverse troponoids.
Here, 92 natural and synthetic troponoids were screened for
inhibition of bacterial growth to assess whether they may be
attractive candidates for development into novel antibiotics.
■ RESULTS
Primary Inhibitor Screening. We measured the eﬀect of
the troponoids on bacterial growth to test whether they had
antibiotic activity. Among the 92 troponoids tested, 18 are
tropolones, 26 are tropones and 48 are α-HT. In the initial
qualitative screening, the 92 compounds were each tested at
5.8, 20.4, and 71.4 μM. We screened against Escherichia coli
(ATCC 35218), Staphylococcus saprophyticus (ATCC BAA-
750), Acinetobacter baumannii (Ab1, from a patient), and P.
aeruginosa (ATCC 27853). The compounds were diluted in
cation-adjusted Mueller-Hinton II broth (CAMHB), and
bacteria from overnight cultures were added to the diluted
compounds in a 96-well plate (5 × 105 CFU/mL inoculum for
each well). After 16−24 h incubation at 35 ± 2 °C, the
turbidity in the cultures was read at 630 nM in a microplate
reader. The percentages of compounds that suppressed
bacterial growth by ≥80% relative to vehicle control cultures
at the screening concentrations are shown for each bacterial
species in Table 1: 9.8 and 8.7% of the compounds inhibited S.
saprophyticus and E. coli growth at 15.2 μM, but at the highest
concentration of 71.4 μM, only 20.4% compounds inhibited A.
baumannii. None of the compounds inhibited P. aeruginosa
growth at 71.4 μM. All results from the full set of 92
troponoids are in shown Table S1.
MIC80 and CC50 Measurement for Troponoids. The
minimal inhibitory concentration 80% (MIC80) and cytotoxic
50% (CC50) values were measured for compounds that
inhibited S. saprophyticus growth by ≥80% at 20.4 μM, and
also those that demonstrated ≥80% inhibition of E. coli and A.
baumannii growth at 71.4 μM in the preliminary screening
(Table 2). An overnight bacterial culture was adjusted to 5 ×
105 CFU/mL and added to 1.5-fold serially diluted
compounds, and turbidity was measured after incubation for
16−24 h. The bacteria (E. coli, A. baumannii, and P.
aeruginosa) used in MIC80 measurements were the same as
for the primary screening, but for Staphylococcus, we shifted to
S. aureus (ATCC 29213) because S. aureus is a common
pathogen in the Staphylococcaceae family, whereas S.
saprophyticus is a commensal member of the normal human
ﬂora. Cytotoxic CC50 values were measured in HepDES19
cells, a HepG2-derived human hepatoblastoma cell line19
because the liver is a common site of drug toxicity. Serially
diluted troponoid compounds were added to HepDES19 cells
in a ﬁnal concentration of dimethyl sulfoxide (DMSO) of 1%.
After 3 days of incubation, MTS reagent was added to cells and
the cells were incubated for 90 min prior to reading absorbance
at 480 nm, and CC50 values were calculated by nonlinear curve
ﬁtting. Therapeutic index (TI) values, the ratio of the amount
of a compound that causes 50% toxicity to the amount that
causes 80% eﬃcacy (CC50/MIC80), were also calculated.
Table 2 shows the MIC80, CC50, and TI values and the
structures of compounds that inhibited ≥80% growth of S.
aureus at <20 μM, and E. coli and A. baumannii at <30 μM with
CC50 >50 μM. Table S1 shows MIC80 and CC50 values for all
92 troponoids.
Among the 18 tropolones that inhibited S. aureus, 53, 54,
and 338 inhibited growth by >80% at <20 μM with CC50s >50
μM and TI values of 8.5, 6.0, and 5.1, respectively. Compound
350 inhibited by >80% at 8.8 μM, but its CC50 was less than 50
μM (46 μM). The rest of the tropolones, 47 to 50, 52, 55,
195, 340 to 345, and 349 had moderate substitutions on the
tropone ring and had decreased or no activity. The 26 tropones
tested were all variants of 53 with modiﬁcations to the
tropolone hydroxyl, and they had variable activities. The −OH
was changed to a chlorine in 57, to an aniline in 60, and to a
sulfonyl ester in 61. All three had MIC80 >100 μM. However,
in 363, the oxygen of the hydroxyl group was changed to
sulfur, and activity was only slightly decreased. Inhibition by
several benzoylated variants (62, 63, 282, 283, 284, 285, 348,
and 364) was similar to that of 53. However, two benzoylated
variants (61 and 346) lost all activity, probably because of
sulfonyl ester replacement. When the thioester in 284 was
changed to a thioether in 365, all inhibitory activity was lost.
For the 48 α-HT compounds, six compounds with appendages
on the troponoid ring (46, 114, 120, 146, 261, and 262)
inhibited S. aureus at <20 μM. In contrast, 172, which has no
substitutions, had an MIC of 66.7 μM.
Regarding the antibacterial activity of troponoids on Gram-
negative rods, including E. coli, Acinetobacter banmannii and P.
aeruginosa, four tropones (284, 363, 364 and 680) and two α-
HT (261 and 310) inhibited E. coli growth by >80% at <30
μM with CC50 values >50 μM. Only two α-HTs (261 and
310) could inhibit A. baumannii by >80% at <30 μM with
CC50s >50 μM. None of the compounds inhibited P.
aeruginosa at 71.4 μM, the highest concentration employed.
Inhibition of Multidrug-Resistant S. aureus Strains by
Compounds 63 and 285. Next, we selected the top two
Figure 1. Structures of (A) tropone, (B) tropolone, and (C) α-HT.
Structures for all compounds tested are in Figure S1.
Table 1. Percentage of Compounds That Inhibited Bacteria
Growth ≥80% Compared to Vehicle-Treatment Control
organism compounds concentration (μM) 5.8 20.4 71.4
S. saprophyticus percentage of compounds (%) 0 9.8 39.1
E. coli percentage of compounds (%) 0 8.7 20.7
A. baumannii percentage of compounds (%) 0 0 15.2
P. aeruginosa percentage of compounds (%) 0 0 0
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Table 2. MIC80 and TI Values of E. coli, S. aureus, A. baumannii, and P. aeruginosa and CC50 for Selected Compounds
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Table 2. continued
aThe therapeutic index, TI, (CC50/MIC80) is provided in parentheses to the right of the MIC80 values. MIC80 >71.4 μM.
Table 3. MIC80 on S. aureus ATCC Strains and MRSA
a
antibiotics
compounds
MIC80 (μM)
bacteria strains FOX OXA GEN CIP ERY CLI LZD DAP VAN TET RIF SXT 63 285
ATCC BAA 1026 POS R R R R R S S S S S R 8.8 8.8
ATCC 25923 Neg S S S S S S S S S S S 8.8 8.8
ATCC BAA 976 POS R S S R S S S S S S S 13.2 8.8
ATCC BAA 977 Neg S S S R R S S S S S S 8.8 8.8
ATCC 29213 Neg S S S S S S S S S S S 8.8 8.8
Sa1 POS R S R R R S S S S S R 8.8 8.8
Sa2 POS R S R R S S S S S S S 8.8 8.8
Sa3 POS R S R R R S S S S S S 8.8 8.8
Sa5 POS R S R R R S S S S 8.8 8.8
Sa6 POS R S R R R S S S S S S 8.8 8.8
Sa7 POS R S S R S S S S S S S 8.8 8.8
Sa8 POS R S R R S S S S 8.8 8.8
Sa9 POS R S R R R S S S S S S 8.8 8.8
Sa10 POS R S R R R S S S 8.8 8.8
Sa11 POS R S R R R S S S S S S 8.8 8.8
Sa12 POS R S R R R S S S S S S 8.8 8.8
Sa14 POS R S R R R S S S S S 8.8 8.8
Sa15 POS R S R R R S S S S R R 8.8 5.9
Sa16 POS R S R R R S S S S S S 8.8 8.8
Sa17 POS R S R R S S S S S S S 8.8 8.8
Sa18 POS R S R R S S S S S S S 8.8 8.8
Sa19 POS R S S R R S S S S S S 8.8 8.8
Sa21 POS R S S R S S S S S S S 8.8 5.9
aR: resistance; S: sensitive; I: intermediate. Sa: MRSA. Cefoxitin (FOX); oxacillin (OXA); gentamicin (GEN); ciproﬂoxacin (CIP); erythromycin
(ERY); clindamycin (CLI); linezolid (LZD); daptomycin (DAP); vancomycin (VAN); tetracycline (TET); rifampin (RIF); trimethoprim−
sulfamethoxazole (SXT).
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primary hits against S. Saprophyticus and S. aureus based on
MIC80 and CC50 values, 63 and 285, to determine if they
inhibit other S. aureus ATCC strains and methicillin-resistant S.
aureus (MRSA). The MRSA strains were collected at the St
Louis VA Medical Center (STLVAMC) under STLVAMC
Subcommittee on Research Safety (SRS)-approved protocols.
All MRSA strains are cefoxitin-screen positive and resistant to
oxacillin. As shown in Table 3, the MIC80 of compounds 63
and 285 against S. aureus ATCC strains and clinical MRSA
strains ranged from 5.9 to 13.2 μM, similar to the value (8.8
μM) against the S. aureus strain (ATCC 29213) used for the
initial MIC80 measurements. In addition to being resistant to
oxacillin, 15 of 18 MRSA strains were also resistant to the
ﬂuoroquinolone class antibiotic ciproﬂoxacin, 12 were resistant
to protein synthesis inhibitor class antibiotic clindamycin, one
was resistant to the DNA-dependent RNA polymerase
inhibitor class antibiotic rifampicin, and two were resistant to
the folate synthesis inhibitor class antibiotic trimethoprim/
sulfamethoxazole. Compounds 63 and 285 had similar potency
in all drug-resistant S. aureus strains, indicating that they have
diﬀerent target(s) from the existing antibiotics tested against
which the strains had been proﬁled.
Inhibition of Multidrug-Resistant Gram-Negative
Strains by Compounds 284, 363, and 261. Compounds
284 and 363 inhibited growth of E. coli. Therefore, we tested
whether they could inhibit multidrug-resistant (MDR) E. coli.
All tested MDR bacteria are resistant to at least three classes of
antibiotics among quinolones/ﬂuorquinolones, carbapenems,
cephalosporins, aminoglycosides, and piperacillin−tazobactam.
Compounds 284 and 363 inhibited ﬁve MDR E. coli (Ec1-5)
strains with MIC80 values ≤30 μM (Table 4). We also tested
261, an inhibitor of A. baumannii, for inhibition of ﬁve MDR A.
baumannii strains and found that it inhibited them with MIC80
≤30 μM (Table 4).
Time-Killing Curves and Bactericidal/Bacteriostatic
Measurements. We next determined time-killing curves of
representative inhibitors and whether they were bactericidal or
bacteriostatic against S. aureus (ATCC 29213) and E. coli
(ATCC 35218) strains. Compounds were diluted into
CAMHB medium to a ﬁnal concentration of 0, 1, 4, and 16
times their MIC80s. Overnight cultures of the test bacteria were
added to the compounds. Samples were taken immediately and
approximately 3, 6, 24, and 30 h after the addition of
compounds and plated onto blood agar. The numbers of
colonies appearing on the plate after 24 h of incubation at 37
°C were counted. Compounds 63 and 285 reduced the colony
count by only 1 log10 unit within 24 h in 1× MIC80. However,
at 4× MIC80, they completely killed the bacteria after 5 or 8 h,
while at 16× MIC80, there was only a 2 log10 reduction in the
colony count within 24 h for both 63 and 285. This
paradoxical eﬀect in which inhibition decreases over a range
of increasing compound concentrations has been previously
observed with β-thujaplicin (47 in our nomenclature).8 A
similar paradoxical eﬀect has also been described for β-lactam
antibiotics against Gram positive bacteria20−22 and for other
antibiotics−microorganism combinations.23,24 This phenom-
enon, which was demonstrated in vitro and in vivo,24 is related
to β-lactamase production,24 alteration in the synthesis or
activity of an autolysin,25 binding to human albumin, as well as
high-density inoculum of stationary cells.26
The time-killing curves for compounds 284 and 363 against
E. coli revealed a 1−2 log10 reduction from 4 to 30 h for 1× and
4× MIC80. At 16× MIC80, there was about a 3 log10 reduction
within 6 h, then about a 2−4 log10 reduction after 24 h for 284
and 363. These results indicate that the troponoids can be
bacteriostatic for E. coli and bactericidal for S. aureus under
certain doses and compound exposures.
Compounds 63 and 285 Inhibit S. aureus Independ-
ently of the Capsule and the CapF Protein. Nakano et al.
reported that 3-isopropenyl-tropolone (349) can bind to
CapF, which catalyzes synthesis of a key precursor of capsular
polysaccharide.27 Therefore, we asked if the MIC80s of 63, 285,
and 349 against S. aureus strains G01 and F4 were altered
relative to strain Newman. F4 is Newman with ermB-
inactivated cap5F gene and G01 is Newman with the ermB-
inactivated cap5G gene. Production of capsule polysaccharide
is abolished in both the G01 and F4 strains. Compound 349
slightly inhibited the wild-type Newman but did not inhibit the
F4 and G01 strains. However, both 63 and 285 inhibited
Newman, F4 and G01 with similar MIC80s (Table 5). Because
the capsular protein is not essential for bacterial growth, from
this growth inhibition assay, we cannot conclude whether the
CapF is the target of the compounds tested or not, but the
signiﬁcant inhibition and/or killing of both wild type and
capsular protein-ablated mutants indicate that neither capsule
nor CapF protein are essential for action of 63 and 285.
Table 4. MIC80 on MDR Enterobacteriaceae for Compounds 284 and 363 and on MDR A. baumannii for Compound 261
a
antibiotics compounds MIC80 (μM)
bacteria strains ESBL SAM TZP CFZ CRO IPM GEN TOB CIP NIT SXT 284 363 261
E. coli 35218 NEG S S S S S S S S S S 13.2 14.8 29.6
Ec1 POS R S R R S R I S S R 19.8 22.2
Ec2 POS I S R R S R I R S R 13.2 9.8
Ec3 POS I S R R S R I S S R 13.2 9.8
Ec4 POS R S R R S S R R S S 19.8 14.8
Ec5 POS R S R R S S R R S R 19.8 19.8
Ab1 S R R S S S R R R 29.6
Ab2 S R R I R S R R R 19.8
Ab3 S R R R I R S R R R 19.8
Ab4 S R R I R S R R R 19.8
Ab5 I R R R R I R R R 29.6
aR: resistance; S: sensitive; I: intermediate. Ec: E. coli; Ab: Acinetobacter baumannii. Extended spectrum beta-lactamases (ESBL); ampicillin−
sulbactam (SAM); piperacillin−tazobactam (TZP); cefazolin (CFZ); ceftriaxone (CRO); imipenem (IPM); gentamicin (GEN); tobramycin
(TOB); ciproﬂoxacin (CIP); nitrofurantoin (NIT); trimethoprim−sulfamethoxazole (SXT).
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■ DISCUSSION
In this study, we determined the antibacterial activities of 92
troponoids. Nine tropones (51, 62, 63, 282−285, 348, and
364), three tropolones (53, 54, and 338), and two α-HTs
(261 and 262) inhibited S. aureus/S. saprophyticus growth by
≥80% at <20 μM with CC50s in human cells >50 μM.
Compounds 261, 284, 310, 363, 364, and 680 inhibited E. coli,
and 261 and 310 inhibited A. baumannii growth by ≥80% at
<30 μM with CC50s >50 μM. Compounds 261, 284, 363, and
364, which inhibited Gram-negative bacteria, also inhibited
Gram-positive bacteria modestly, but the opposite is not true,
as 51, 53, 282, 283, 285, 338, and 348 inhibited S. aureus at
<20 μM, but could not inhibit E. coli, A. baumannii, or P.
aeruginosa. The broad anti-bacterial activity of β-thujaplicin
(Hinokitiol, 47) and γ-thujaplicin (48) was reported several
decades ago.8,28,29 Our results revealed modest inhibition of
both Gram-positive bacteria (S. aureus) and Gram-negative
rods (E. coli and A. banmannii), which is consistent with
previous reports (Table S1). Two α-HT, 261 and 262, also
showed broad inhibition against both Gram-positive and
Gram-negative bacteria (Table 2). However, the CC50 values
were around 50 μM, so there is little to no TI compared to
their eﬀects on human cells.
Nine of 15 benzoylated tropolones (51, 62, 63, 282, 283,
284, 285, 348, and 364) inhibited growth of S. aureus by
≥80% at <20 μM with CC50 values >50 μM (Table 2). Two
benzoylated tropolones (281 and 339) had modest inhibition.
These benzoylated tropolones all have a troponoid ring
connected to a benzoate through an ester linkage, or in the
case of 284, 348, and 364, a thioester linkage. Because the
addition of the benzene ring did not aﬀect inhibition of
bacterial growth signiﬁcantly, we assume that the benzene ring
is not a primary determinant of antibacterial activity, but they
can aﬀect the interaction between the tropolone ring and the
target.
Compounds 284, 364, and 363 inhibited MDR E. coli with
MIC80 ≤30 μM. 364 is a derivative of 284 lacking the methyl
group on the benzene moiety, and it had an eﬃcacy similar to
284. As the thioester bond in 284 is unlikely to be stable in
culture, we synthesized one of the putative esterase products,
thiotropolone (compound 363). As shown in Table 2, 363 was
more active than 284 (14.8 μM vs 24.1 μM). This indicates
that the minimal active component of our primary screening
hit was thiotropolone 363. To expand the assessment of
thiotropolones as inhibitors of E. coli growth, Dr. Elgendy
synthesized 10 new compounds with diﬀerent modiﬁcations on
the troponoid ring and the right arm (677−686). Compounds
677, 678, 680, 681, 684, and 685 have the thiotropolone core
structure and they inhibited E. coli growth at <20 μM (Table
S1 and Figure S1). As expected, compound 683, which has the
oxygen replaced sulfur atom next to the ketone group on the
troponoid ring, is inactive against E. coli. Compound 686 has
the thiotropolone core, but is inactive, indicating that the right
arm somehow participates in the interaction of thiotropolone
with the bacterial target, potentiates compound degradation,
and/or induces their eﬄux from the cells. These data further
demonstrate that thiotropolone is the core structure in these
compounds for the anti-bacterial activity against E. coli, but
that modiﬁcations to the tropolone ring and thiol moieties can
aﬀect eﬃcacy. 284 and 363 can also inhibit growth of the
fungal pathogen Cryptococcus neoformans with an MIC80 of
0.25 μM15 and unpublished data. However, it is unknown
whether they inhibit the bacteria and C. neoformans by the
same mechanisms.
Two compounds, 63 and 285, also inhibited other S. aureus
ATCC strains and MRSA S. aureus strains collected from
patients with similar MIC80 values as against ATCC reference
strains. These clinical isolates and ATCC strains had extensive
but diﬀering resistance patterns to a set of common clinically
relevant antibiotics including oxacillin, gentamicin, ciproﬂox-
acin, erythromycin, clindamycin, and trimethoprim−sulfame-
thoxazole in addition to methicillin. For Gram-negative rods,
compounds 284, 363, and 364 inhibited E. coli and MDR-E.
coli with MIC80 ≤30 μM. Meanwhile, compound 261 inhibited
MDR A. baumannii with MIC80 ≤30 μM. These clinical
isolates also had extensive but diﬀering resistance patterns to a
set of common clinically relevant antibiotics including
ampicillin−sulbactam, piperacillin−tazobactam, cefazolin, cef-
triaxone, cefepime, gentamicin, tobramycin, ciproﬂoxacin,
nitrofurantoin, and trimethoprim−sulfamethoxazole. The
inhibition of these MDR bacteria indicates the compounds
tested, and possibly the other troponoids, have diﬀerent
bacterial targets from the common existing antibiotics.
The biological eﬀects of troponoid compounds are typically
due to coordination of cations in the active sites of
metalloenzymes.30−32 For example, the α-HTs inhibit the
HIV ribonuclease H by coordinating the two Mg2+ ions in the
active site,33 and they are believed to act the same way against
the hepatitis B virus ribonuclease H.34 Similarly, tropolone has
been reported to inhibit several Zn2+-dependent metal-
loenzymes.35−37 Finally, CapF is a bifunctional metalloenzyme
which is essential in the biosynthetic route of capsular
polysaccharide. Isothermal titration calorimetry demonstrates
that 3-isopropenyl-tropolone (349) binds (Kd = 27 ± 7 μM)
to the cupin domain of CapF. In addition, the crystal structure
of the enzyme−inhibitor complex shows that the compound
engages the essential Zn2+ ion necessary for the ﬁrst reaction
catalyzed by the enzyme and alters the coordination sphere of
the metal, leading to the overall destabilization of the
enzyme.27 However, from the MIC80 against S. aureus Newman
and F4 (with ermB-inactivated cap5F gene), 349 can only
slightly inhibit Newman growth and cannot inhibit the F4
growth, while 63 and 285 can signiﬁcantly inhibit the growth
of Newman and F4. In addition, the time-killing assay showed
that 63 and 285 are bactericidal for a MRSA strain. Although
this growth inhibition assay does not distinguish whether 63
and 285 can bind to CapF or not, we can conclude that the
target(s) of 63 and 285 must be something in addition to or
other than CapF because the capsule is not essential for the
growth of S. aureus. Through screening of a chelator fragment
library, tropolone was identiﬁed as an inhibitor of the Zn2+-
dependent virulence factor, P. aeruginosa elastase (LasB).37
However, none of the troponoid compounds inhibited growth
of P. aeruginosa at <71.4 μM in our assay. This could be
because LasB is not essential for the growth of P. aeruginosa,
Table 5. MIC80 of S. aureus Newman, G01, and F4 for
Selected Compounds
MIC80 (μM)
comp# Newmana F4a G01a
63 13.2 13.2 13.2
285 13.2 13.2 13.2
349 66.7 100 100
aS. aureus.
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although our growth inhibition assay cannot determine
whether the troponoids bind to LasB or not. The
mechanism(s) of troponoid inhibition is unknown, but the
bactericidal property of investigated compounds (63 and 285,
Figure 2) in certain concentrations indicates that they disrupt
the function of bacterial target(s) essential for bacterial
viability.
These data greatly expand knowledge regarding the
antibacterial eﬃcacy of the troponoids. Importantly, the
activity of these compounds against a panel of highly drug-
resistant Gram-positive and Gram-negative bacteria indicates
that they act by mechanism(s) distinct from existing clinically
used antibiotics. Therefore, this study opens up a new avenue
for development of novel troponoids antibiotics to address the
critical and urgent need for novel drugs to combat serious
bacterial infections.
■ EXPERIMENTAL SECTION
Compound Acquisition and Synthesis. The compounds
employed are listed in Table S1.
Compounds were acquired commercially or were synthe-
sized as described below. Compounds 46−57 and 195 were
acquired from the National Cancer Institute (NCI) Devel-
opmental Therapeutics Program. Compounds 60−63, 210,
281−285, and 348−350 were purchased. Compound 172 was
synthesized according to a published procedure.38 Compounds
106−120, 143−147, 173, 273−274, and 335 were synthetized
from kojic acid as previously described.11,39−41 Compounds
257−259, 280, 308−313, 315, 317−319, 336, and 347 were
synthesized as previously described.15,42 Compounds 261−264
were made using the Banwell method.43 Compound 363 was
synthesized from 2-cholorotropone and sodium hydrosulﬁde.44
Compound 364 was synthesized from 363 according to the
procedure of Nozoe.45 Compound 365 was synthesized
according to a published procedure.46 For the synthesis of
compounds 675−682, 684−686 (675 = 363 and 676 = 364),
see Supporting Information Compounds were ≥95% pure by
1H NMR analysis. The analytical data for all published
compounds are consistent with that reported previously. They
were dissolved in DMSO at 10 mM and stored in opaque tubes
at −80 °C.
Bacterial Strains. The commercially acquired bacterial
strains were obtained from the American Type Culture
Collection (ATCC). The clinical MRSA, MDR Enterobacter-
iaceae, and A. baumannii strains were collected from the
microbiology laboratory at the John Cochran division of the St.
Louis VA Health care system (STLVAHCS) under
STLVAHCS Subcommittee on Research Safety (SRS)-
approved protocols. S. aureus Newman, G01, and F4 were
kindly provided by Dr. Jean Lee. G01 is Newman with ermB-
inactivated cap5G gene and F4 is Newman with ermB-
inactivated cap5F gene.47
Determination of the Minimum Inhibitory Concen-
tration. MIC80s were determined by the broth microdilution
method recommended by the Clinical and Laboratory
Standards Institute (CLSI) in CAMHB. In the preliminary
screening, three compound concentrations were used: 5.8,
20.4, and 71.4 μM; In quantitative MIC80 measurements, a 1.5-
fold dilution series of the compounds was prepared in
CAMHB. Overnight bacterial culture was added to the diluted
compounds in a 96-well plate after adjusting the bacterial
concentration to achieve a 5 × 105 CFU/mL ﬁnal
concentration. After 16−24 h incubation at 35 ± 2 °C, the
plates were read at 630 nM in a microplate reader. The MIC80
was deﬁned as the concentration of an antibacterial agent that
inhibited bacteria growth ≥80% compared to untreated control
cultures. All values were determined at least twice
independently, and the average number is reported.
MTS Cytotoxicity Assays (CC50). HepDES19 cells
19 (1.0
× 104 cells per well) were seeded in 96-well plates and
Figure 2. Time-killing curves for compounds 63 and 285 against S. aureus (ATCC 29213) and for 284 and 363 against E. coli (ATCC 35218).
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incubated in Dulbecco’s modiﬁed eagle medium with 10% fetal
bovine serum plus 1% penicillin/streptomycin solution, 1%
nonessential amino acids, and 1% glutamine. The compounds
were diluted in the medium to the indicated concentrations to
a ﬁnal concentration of 1% DMSO and added to the cells 48 h
after plating, with each concentration tested in triplicate.
Soluble MTS reagent [3-(4,5-dimethylthiazol-2-yl)-5-(3-car-
boxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
Promega] was added 72 h after incubation, the cultures were
incubated for 90 min, and absorbance was read at 490 nm. The
CC50 was calculated as the concentration of the inhibitor
required to reduce cell viability 50% relative to untreated cells.
The data are plotted as log[inhibitor] versus response and ﬁt to
a variable slope model using Graph Pad Prism.15
Time-Killing Curve and Bactericidal/Bacteriostatic
Measurement. Compounds were diluted into CAMHB
medium containing 0 (vehicle-treatment control), 1, 4, or 16
times the MIC80. Approximately 10
5 CFU/mL of the test
bacteria from overnight cultures were added to the compound
solutions. Samples were taken immediately and 3, 6, 24, and 30
h after the addition of compounds and plated onto blood agar.
The numbers of colonies appearing on the plate after 24 h of
incubation at 37 °C were counted.48
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(44) Nozoe, T.; Satô, M.; Matsui, K. Mercaptotropone and some of
its allied compounds. Proc. Jpn. Acad. 1953, 29, 22−26.
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